ClinicalTrials.gg
RecruitingNCT03121001Updated Jul 8, 2026

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

A Phase 2 interventional study of ATG and fludarabine in Sickle Cell Disease, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by University of Illinois at Chicago · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2017; still recruiting 9 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
16 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing fludarabine in Anemia, Sickle Cell — 4 open to participants now, 8 under way, none of them phase 3. fludarabine · Anemia, Sickle Cell.

Planned enrollment
5th of 22
50 · median 21
Started
2017
with 3 others
Phase 2
12 of 22
3 open now
Registered
16th of 22
by date

Among the 22 studies testing fludarabine in Anemia, Sickle Cell, this one is the 5th largest by planned enrollment, is one of 4 that started in 2017, is one of 12 in phase 2, and was the 16th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 22 studies testing fludarabine in Anemia, Sickle Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 16 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing fludarabine in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT).

The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Eligibility:

  1. Patients with sickle cell disease are eligible if they have any of the following complications:

    1.1 Stroke or central nervous system event lasting longer than 24 hours 1.2 Frequent vaso-occlusive pain episodes, defined as ≥ 3 per year requiring emergency room, acute care center, hospital admissions, or home bedrest leading to absence from work or school. 1.3 Recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room visits 1.4 Acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime events 1.5 Red-cell alloimmunization (≥ 2 antibodies) during long-term transfusion therapy 1.6 Bilateral proliferative retinopathy with major visual impairment in at least one eye 1.7 Osteonecrosis of 2 or more joints 1.8 Sickle cell nephropathy, defined by a \< 90mL/min/1.73m2 or the presence of macroalbuminuria (urine albumin > 300 mg/g creatinine) 1.9 Pulmonary hypertension, defined by a mean pulmonary arterypressure >25mmHg

  2. Age 16-60 years
  3. performance status of 60 or higher (Appendix A)
  4. Adequate cardiac function, defined as ≥ 40%
  5. Adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥ 50% predicted (after adjustment for concentration)
  6. Estimated GFR ≥ 50mL/min/1.73m2 as calculated by the modified MDRD equation
  7. ≤ 3x
  8. -negative
  9. Patient is not pregnant
  10. Patient is able and willing to sign
  11. Patient does not have a fully HLA-matched sibling donor
  12. Patient has an HLA-haploidentical relative

Donor Eligibility Relatives (parents, offspring, siblings, aunts/uncles, cousins) will be tested by molecular typing of HLA class I (A, B, and C) and class II (DRB1) at low resolution. Only those that are an HLA-haploidentical match (≥ 4/8) will be considered as a potential donor. NOTE: If during testing, a fully HLA-matched sibling donor is found and is willing to donate his/her stem cells, the potential subject will not be eligible for this protocol.

Donor consent will be obtained as per standard protocol of the bone marrow transplant unit.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Subject treatment

    Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter.

    Drug: ATG · Drug: fludarabine · Drug: cyclophosphamide · Radiation: Total body irradiation · Procedure: Stem cell infusion · Drug: Sirolimus · Drug: mycophenolate mofetil

Interventions

  • DrugAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7

    Also known as: Thymoglobulin®

  • 30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2

  • 14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4

  • RadiationTotal body irradiation

    3 Gy on day -1

  • ProcedureStem cell infusion

    Stem cell product infused according to BMT unit policy on day 0.

  • loading dose of 15 mg followed by 5 mg per day on day +5

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 g every 8 h (until day 35) will be started on day 5

06

What researchers measure

Primary outcomes

  1. Estimate the number of patients who engraft by Day +60

    Patients who achieve \< 5% peripheral blood donor chimerism by Day +30 and do not have a Day +60 measure will be regarded as failing to achieve full donor chimerism by Day +60; patients who achieve \> 5% donor chimerism by Day +30 but do not have a Day +60 measure will be considered nonevaluable for the primary endpoint.

    Time frame: Up to Day +60

Secondary outcomes

  1. Disease free survival

    Using the Kaplan-Meier method, the probability of EFS will be estimated and reported with 90% confidence intervals. The proportion of patients who are alive will also be estimated with a 90% exact binomial confidence interval. Cumulative incidences of transplant related mortality will be estimated separately using Grey's method.

    Time frame: Up to Day +60

  2. Overall survival

    Using the Kaplan-Meier method, the probability of overall survival will be estimated and reported with 90% confidence intervals. The proportion of patients who are alive will also be estimated with a 90% exact binomial confidence interval. Cumulative incidences of transplant related mortality will be estimated separately using Grey's method.

    Time frame: Up to Day +60

  3. Adverse Effects

    The cumulative incidence of acute (grade II-IV, grade III-IV) and chronic GVHD will be estimated through competing-risk analysis using Grey's method, wherein graft failure, and death are competing risks for GVHD. Other selected toxicities (including rates of infection) will be reported descriptively.

    Time frame: Up to Day +60

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for May 2029, 146 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 146 months is above that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2017
First posted
Apr 19, 2017
StartActual
Mar 20, 2017
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03121001
Responsible party
Damiano Rondelli, MD (Professor, Hematology, University of Illinois at Chicago) — Principal investigator
First posted
Apr 19, 2017
Start date
Mar 20, 2017
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jul 8, 2026

Study contacts

Damiano Rondelli, MD
Contact
drond@uic.edu
312 413-3547
Damiano Rondelli, MD
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antilymphocyte Serum · Fludarabine · Cyclophosphamide · Sirolimus · Mycophenolic Acid

Start the discussion